Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma

Annals of Surgery

Volumn 255, Issue 2, 2012, Pages 357-362

  Hoshimoto, Sojun ^a   Faries, Mark B ^a   Morton, Donald L ^a   Shingai, Tatsushi ^a   Kuo, Christine ^a   Wang, He Jing ^b   Elashoff, Robert ^b   Mozzillo, Nicola ^c   Kelley, Mark C ^d   Thompson, John F ^e   Lee, Jeffrey E ^f   Hoon, Dave S B ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; LACTATE DEHYDROGENASE; MELAN A; MELANOMA ANTIGEN 3; MESSENGER RNA; ONAMELATUCEL L; PLACEBO; TICE STRAIN; TRANSCRIPTION FACTOR PAX3; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CIRCULATING TUMOR CELL; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS RESECTION; MULTICENTER STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEX DIFFERENCE;

ADULT; AGED; ANTIGENS, NEOPLASM; CANCER VACCINES; CHEMOTHERAPY, ADJUVANT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MART-1 ANTIGEN; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; PAIRED BOX TRANSCRIPTION FACTORS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84862806703     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3182380f56     Document Type: Article

References (37)

1. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg. 1995;181:193-201.
2. Ollila DW. Complete metastasectomy in patients with stage IV metastatic melanoma. Lancet Oncol. 2006;7:919-924. (Pubitemid 44615951)
3. Morton DL, Hsueh EC, Essner R, et al. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection ofmelanomametastatic to regional lymph nodes. Ann Surg. 2002;236:438-448; discussion 448-449.
4. Ollila DW, Stern SL, Morton DL. Tumor doubling time: a selection factor for pulmonary resection ofmetastatic melanoma. J Surg Oncol. 1998;69:206-211. (Pubitemid 29024563)
5. Mocellin S, Del Fiore P, Guarnieri L, et al. Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma. Int J Cancer. 2004;111:741-745. (Pubitemid 39062897)
6. Mocellin S, Hoon D, Ambrosi A, et al. The prognostic value of circulating tumor cells in patients with melanoma: a systematic review and meta-analysis. Clin Cancer Res. 2006;12:4605-4613. (Pubitemid 44297811)
7. Mellado B, Colomer D, Castel T, et al. Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis. J Clin Oncol. 1996;14:2091-2097. (Pubitemid 26230111)
8. Curry BJ, Myers K, Hersey P.MART-1 is expressed less frequently on circulatingmelanoma cells in patientswho develop distant compared with locoregional metastases. J Clin Oncol. 1999;17:2562-2571. (Pubitemid 29368259)
9. Gogas H, Kefala G, Bafaloukos D, et al. Prognostic significance of the sequential detection of circulating melanoma cells by RT-PCR in high-risk melanoma patients receiving adjuvant interferon. Br J Cancer. 2002;87:181-186.
10. Palmieri G, Ascierto PA, Perrone F, et al. Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction. J Clin Oncol. 2003;21:767-773. (Pubitemid 46606433)
11. Keilholz U, Goldin-Lang P, Bechrakis NE, et al. Quantitative detection of circulating tumor cells in cutaneous and ocular melanoma and quality assessment by real-time reverse transcriptase-polymerase chain reaction. Clin Cancer Res. 2004;10:1605-1612. (Pubitemid 38435549)
12. Koyanagi K, O'Day SJ, Gonzalez R, et al. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. J Clin Oncol. 2005;23:8057-8064. (Pubitemid 46657408)
13. Hoon DS, Bostick P, Kuo C, et al. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res. 2000;60:2253-2257. (Pubitemid 30225191)
14. Morton DL, Mozzillo N, Thompson JF, et al. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. J Clin Oncol. 2007 ASCO Annual Meeting Proceedings. 2007;25; 474S:Abstract 8508.
15. Takeuchi H, Morton DL, Kuo C, et al. Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J Clin Oncol. 2004;22:2671-2680. (Pubitemid 41103755)
16. Nicholl MB, Elashoff D, Takeuchi H, et al. Molecular upstaging based on paraffin-embedded sentinel lymph nodes: ten-year follow-up confirms prognostic utility in melanoma patients. Ann Surg. 2011;253:116-122.
17. Koyanagi K, O'Day SJ, Boasberg P, et al. Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res. 2010;16:2402-2408.
18. BuyseM, Sargent DJ, Grothey A, et al. Biomarkers and surrogate end points-the challenge of statistical validation. Nat Rev Clin Oncol. 2010;7:309-317.
19. McShane LM, Altman DG, Sauerbrei W, et al. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Oncol. 2005;2:416-422. (Pubitemid 43115010)
20. Fleming ID, Cooper JS, Henson DE, et al. American Joint Committee on Cancer: AJCC Cancer Staging Manual. 5th ed. Philadelphia, PA: Lippincott-Raven; 1997.
21. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Veriag; 2002.
22. Koyanagi K, Bilchik AJ, Saha S, et al. Prognostic relevance of occult nodal micrometastases and circulating tumor cells in colorectal cancer in a prospective multicenter trial. Clin Cancer Res. 2008;14:7391-7396.
23. Koyanagi K, Kuo C, Nakagawa T, et al. Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients. Clin Chem. 2005;51:981-988. (Pubitemid 40740878)
24. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622-3634. (Pubitemid 32786275)
25. Bostick PJ, Chatterjee S, Chi DD, et al. Limitations of specific reversetranscriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients. J Clin Oncol. 1998;16:2632-2640. (Pubitemid 28363026)
26. Jung FA, BuzaidAC, Ross MI, et al. Evaluation of tyrosinasemRNAas a tumor marker in the blood of melanoma patients. J Clin Oncol. 1997;15:2826-2831. (Pubitemid 27330009)
27. Mocellin S, Hoon DS, Pilati P, et al. Sentinel lymph node molecular ultrastaging in patientswith melanoma: a systematic reviewandmeta-analysis of prognosis. J Clin Oncol. 2007;25:1588-1595. (Pubitemid 46733087)
28. Gast A, Scherer D, Chen B, et al. Somatic alterations in themelanoma genome: a high-resolution array-based comparative genomic hybridization study. Genes Chromosomes Cancer. 2010;49:733-745.
29. Sarantou T, Chi DD, Garrison DA, et al. Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Res. 1997;57:1371-1376. (Pubitemid 27152564)
30. Scolyer RA,MihmMCJ, Cochran AJ, et al. Pathology ofmelanoma. In: Balch CM, Houghton AN, Sober AJ, et al., eds. Cutaneous Melanoma, Vol. 5. St. Louis, MO: Quality Medical Publishing, Inc.; 2009.
31. Kitago M, Koyanagi K, Nakamura T, et al. mRNA expression and BRAF mutation in circulatingmelanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads. Clin Chem. 2009;55:757-764.
32. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781-791. (Pubitemid 39095313)
33. Sieuwerts AM, Kraan J, Bolt-de Vries J, et al. Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR. Breast Cancer Res Treat 2009; 118:455-468.
34. Kuo CT, Hoon DS, Takeuchi H, et al. Prediction of disease outcome in melanoma patients by molecular analysis of paraffin-embedded sentinel lymph nodes. J Clin Oncol. 2003;21:3566-3572. (Pubitemid 46594047)
35. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
36. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363:809-819.
37. Hersh E, Millward M, Elias I, Iglesias J. An open-label, multicenter, phase II trial of nab-paclitaxel (NP) versus dacarbazine (DTIC) in previously untreated patients (PTs) with metastatic malignant melanoma (MMM). J Clin Oncol. 2010 ASCO Annual Meeting Proceedings. 2010;28; 59S:Abstract TPS314.